Diaphyseal

Table of contents

32C: i Proximal diaphyseal-metaphyseal, j Pure diaphyseal, k Distal diaphyseal-metaphyseal 33A Extraarticular 33A1 Avulsion 33A2 Simple 33A3 Wedge or multifragmentary 33B Partial articular 33B1 Lateral condyle, sagittal 33B2 Medial condyle, sagittal 33B3 Frontal/coronal 33C Complete articular 33C1 Simple articular, simple metaphyseal

  Diaphyseal

Reference ID: 4121283 - Food and Drug Administration

5.5 Atypical Subtrochanteric and Diaphyseal Femoral Fractures . 5.6 Pregnancy . 5.7 Musculoskeletal Pain . 5.8 Patients with Asthma . 6 ADVERSE REACTIONS . 6.1 . Clinical Trials Experience 6.2 . Post-Marketing Experience . 7 DRUG INTERACTIONS . 7.1 Aminoglycosides . 7.2 Loop Diuretics . 7.3 Nephrotoxic Drugs . 7.4 Drugs Primarily Excreted by ...

  Administration, Drug, Food and drug administration, Food, Diaphyseal

HIGHLIGHTS OF PRESCRIBING INFORMATION - Amgen

5.5 Atypical Subtrochanteric and Diaphyseal Femoral Fracture 5.6 Hypercalcemia Following Treatment Discontinuation in Patients with Giant Cell Tumor of Bone and in Patients with Growing Skeletons 5.7 Multiple Vertebral Fractures (MVF) Following Treatment Discontinuation 5.8 Embryo-Fetal Toxicity 6 ADVERSE REACTIONS 6.1 Clinical Trials Experience

  Information, Prescribing, Prescribing information, Diaphyseal

V. Gilsanz/O. Ratib · Hand Bone Age

Bone Development Skeletalmaturityisameasureofdevelopmentincorporatingthesize,shape anddegreeofmineralizationofbonetodefineitsproximitytofullmaturi-